Report cover image

Global Axial Spondyloarthritis Medications Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 199 Pages
SKU # APRC20278167

Description

Summary

According to APO Research, The global Axial Spondyloarthritis Medications market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Axial Spondyloarthritis Medications is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Axial Spondyloarthritis Medications include Abbott, Johnson & Johnson, Novartis, Pfizer, Bayer, Verywell, UCB, Sun Pharmaceutical Industries and Reddy Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Axial Spondyloarthritis Medications, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Axial Spondyloarthritis Medications, also provides the sales of main regions and countries. Of the upcoming market potential for Axial Spondyloarthritis Medications, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Axial Spondyloarthritis Medications sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Axial Spondyloarthritis Medications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Axial Spondyloarthritis Medications sales, projected growth trends, production technology, application and end-user industry.

Axial Spondyloarthritis Medications Segment by Company

Abbott
Johnson & Johnson
Novartis
Pfizer
Bayer
Verywell
UCB
Sun Pharmaceutical Industries
Reddy Pharmaceuticals
Perrigo Company
Novacap
Merck Sharp & Dohme
Kopran
GlaxoSmithKline
Geri-Care Pharmaceuticals
Eli Lilly and Co.
DICE Therapeutics
Cigna
AstraZeneca
Axial Spondyloarthritis Medications Segment by Type

Injection
Oral
Axial Spondyloarthritis Medications Segment by Application

Hospital
Clinic
Other
Axial Spondyloarthritis Medications Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axial Spondyloarthritis Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Axial Spondyloarthritis Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axial Spondyloarthritis Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Axial Spondyloarthritis Medications market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Axial Spondyloarthritis Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Axial Spondyloarthritis Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Axial Spondyloarthritis Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Axial Spondyloarthritis Medications Market Size, 2020 VS 2024 VS 2031
1.3 Global Axial Spondyloarthritis Medications Market Size Estimates and Forecasts (2020-2031)
1.4 Global Axial Spondyloarthritis Medications Sales Estimates and Forecasts (2020-2031)
1.5 Global Axial Spondyloarthritis Medications Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Axial Spondyloarthritis Medications Market Dynamics
2.1 Axial Spondyloarthritis Medications Industry Trends
2.2 Axial Spondyloarthritis Medications Industry Drivers
2.3 Axial Spondyloarthritis Medications Industry Opportunities and Challenges
2.4 Axial Spondyloarthritis Medications Industry Restraints
3 Axial Spondyloarthritis Medications Market by Manufacturers
3.1 Global Axial Spondyloarthritis Medications Revenue by Manufacturers (2020-2025)
3.2 Global Axial Spondyloarthritis Medications Sales by Manufacturers (2020-2025)
3.3 Global Axial Spondyloarthritis Medications Average Sales Price by Manufacturers (2020-2025)
3.4 Global Axial Spondyloarthritis Medications Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Axial Spondyloarthritis Medications Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Axial Spondyloarthritis Medications Manufacturers, Product Type & Application
3.7 Global Axial Spondyloarthritis Medications Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Axial Spondyloarthritis Medications Market CR5 and HHI
3.8.2 Global Top 5 and 10 Axial Spondyloarthritis Medications Players Market Share by Revenue in 2024
3.8.3 2024 Axial Spondyloarthritis Medications Tier 1, Tier 2, and Tier 3
4 Axial Spondyloarthritis Medications Market by Type
4.1 Axial Spondyloarthritis Medications Type Introduction
4.1.1 Injection
4.1.2 Oral
4.2 Global Axial Spondyloarthritis Medications Sales by Type
4.2.1 Global Axial Spondyloarthritis Medications Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Axial Spondyloarthritis Medications Sales by Type (2020-2031)
4.2.3 Global Axial Spondyloarthritis Medications Sales Market Share by Type (2020-2031)
4.3 Global Axial Spondyloarthritis Medications Revenue by Type
4.3.1 Global Axial Spondyloarthritis Medications Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Axial Spondyloarthritis Medications Revenue by Type (2020-2031)
4.3.3 Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2020-2031)
5 Axial Spondyloarthritis Medications Market by Application
5.1 Axial Spondyloarthritis Medications Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Other
5.2 Global Axial Spondyloarthritis Medications Sales by Application
5.2.1 Global Axial Spondyloarthritis Medications Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Axial Spondyloarthritis Medications Sales by Application (2020-2031)
5.2.3 Global Axial Spondyloarthritis Medications Sales Market Share by Application (2020-2031)
5.3 Global Axial Spondyloarthritis Medications Revenue by Application
5.3.1 Global Axial Spondyloarthritis Medications Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Axial Spondyloarthritis Medications Revenue by Application (2020-2031)
5.3.3 Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2020-2031)
6 Global Axial Spondyloarthritis Medications Sales by Region
6.1 Global Axial Spondyloarthritis Medications Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Axial Spondyloarthritis Medications Sales by Region (2020-2031)
6.2.1 Global Axial Spondyloarthritis Medications Sales by Region (2020-2025)
6.2.2 Global Axial Spondyloarthritis Medications Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Axial Spondyloarthritis Medications Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Axial Spondyloarthritis Medications Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Axial Spondyloarthritis Medications Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Axial Spondyloarthritis Medications Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Axial Spondyloarthritis Medications Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Axial Spondyloarthritis Medications Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Axial Spondyloarthritis Medications Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Axial Spondyloarthritis Medications Revenue by Region
7.1 Global Axial Spondyloarthritis Medications Revenue by Region
7.1.1 Global Axial Spondyloarthritis Medications Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Axial Spondyloarthritis Medications Revenue by Region (2020-2025)
7.1.3 Global Axial Spondyloarthritis Medications Revenue by Region (2026-2031)
7.1.4 Global Axial Spondyloarthritis Medications Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Axial Spondyloarthritis Medications Revenue (2020-2031)
7.2.2 North America Axial Spondyloarthritis Medications Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Axial Spondyloarthritis Medications Revenue (2020-2031)
7.3.2 Europe Axial Spondyloarthritis Medications Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Axial Spondyloarthritis Medications Revenue (2020-2031)
7.4.2 Asia-Pacific Axial Spondyloarthritis Medications Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Axial Spondyloarthritis Medications Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Axial Spondyloarthritis Medications Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Abbott
8.1.1 Abbott Comapny Information
8.1.2 Abbott Business Overview
8.1.3 Abbott Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Abbott Axial Spondyloarthritis Medications Product Portfolio
8.1.5 Abbott Recent Developments
8.2 Johnson & Johnson
8.2.1 Johnson & Johnson Comapny Information
8.2.2 Johnson & Johnson Business Overview
8.2.3 Johnson & Johnson Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Johnson & Johnson Axial Spondyloarthritis Medications Product Portfolio
8.2.5 Johnson & Johnson Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Axial Spondyloarthritis Medications Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Pfizer Axial Spondyloarthritis Medications Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Bayer
8.5.1 Bayer Comapny Information
8.5.2 Bayer Business Overview
8.5.3 Bayer Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Bayer Axial Spondyloarthritis Medications Product Portfolio
8.5.5 Bayer Recent Developments
8.6 Verywell
8.6.1 Verywell Comapny Information
8.6.2 Verywell Business Overview
8.6.3 Verywell Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Verywell Axial Spondyloarthritis Medications Product Portfolio
8.6.5 Verywell Recent Developments
8.7 UCB
8.7.1 UCB Comapny Information
8.7.2 UCB Business Overview
8.7.3 UCB Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 UCB Axial Spondyloarthritis Medications Product Portfolio
8.7.5 UCB Recent Developments
8.8 Sun Pharmaceutical Industries
8.8.1 Sun Pharmaceutical Industries Comapny Information
8.8.2 Sun Pharmaceutical Industries Business Overview
8.8.3 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Product Portfolio
8.8.5 Sun Pharmaceutical Industries Recent Developments
8.9 Reddy Pharmaceuticals
8.9.1 Reddy Pharmaceuticals Comapny Information
8.9.2 Reddy Pharmaceuticals Business Overview
8.9.3 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
8.9.5 Reddy Pharmaceuticals Recent Developments
8.10 Perrigo Company
8.10.1 Perrigo Company Comapny Information
8.10.2 Perrigo Company Business Overview
8.10.3 Perrigo Company Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Perrigo Company Axial Spondyloarthritis Medications Product Portfolio
8.10.5 Perrigo Company Recent Developments
8.11 Novacap
8.11.1 Novacap Comapny Information
8.11.2 Novacap Business Overview
8.11.3 Novacap Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Novacap Axial Spondyloarthritis Medications Product Portfolio
8.11.5 Novacap Recent Developments
8.12 Merck Sharp & Dohme
8.12.1 Merck Sharp & Dohme Comapny Information
8.12.2 Merck Sharp & Dohme Business Overview
8.12.3 Merck Sharp & Dohme Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Merck Sharp & Dohme Axial Spondyloarthritis Medications Product Portfolio
8.12.5 Merck Sharp & Dohme Recent Developments
8.13 Kopran
8.13.1 Kopran Comapny Information
8.13.2 Kopran Business Overview
8.13.3 Kopran Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Kopran Axial Spondyloarthritis Medications Product Portfolio
8.13.5 Kopran Recent Developments
8.14 GlaxoSmithKline
8.14.1 GlaxoSmithKline Comapny Information
8.14.2 GlaxoSmithKline Business Overview
8.14.3 GlaxoSmithKline Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 GlaxoSmithKline Axial Spondyloarthritis Medications Product Portfolio
8.14.5 GlaxoSmithKline Recent Developments
8.15 Geri-Care Pharmaceuticals
8.15.1 Geri-Care Pharmaceuticals Comapny Information
8.15.2 Geri-Care Pharmaceuticals Business Overview
8.15.3 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
8.15.5 Geri-Care Pharmaceuticals Recent Developments
8.16 Eli Lilly and Co.
8.16.1 Eli Lilly and Co. Comapny Information
8.16.2 Eli Lilly and Co. Business Overview
8.16.3 Eli Lilly and Co. Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.16.4 Eli Lilly and Co. Axial Spondyloarthritis Medications Product Portfolio
8.16.5 Eli Lilly and Co. Recent Developments
8.17 DICE Therapeutics
8.17.1 DICE Therapeutics Comapny Information
8.17.2 DICE Therapeutics Business Overview
8.17.3 DICE Therapeutics Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.17.4 DICE Therapeutics Axial Spondyloarthritis Medications Product Portfolio
8.17.5 DICE Therapeutics Recent Developments
8.18 Cigna
8.18.1 Cigna Comapny Information
8.18.2 Cigna Business Overview
8.18.3 Cigna Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.18.4 Cigna Axial Spondyloarthritis Medications Product Portfolio
8.18.5 Cigna Recent Developments
8.19 AstraZeneca
8.19.1 AstraZeneca Comapny Information
8.19.2 AstraZeneca Business Overview
8.19.3 AstraZeneca Axial Spondyloarthritis Medications Sales, Price, Revenue and Gross Margin (2020-2025)
8.19.4 AstraZeneca Axial Spondyloarthritis Medications Product Portfolio
8.19.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Axial Spondyloarthritis Medications Value Chain Analysis
9.1.1 Axial Spondyloarthritis Medications Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Axial Spondyloarthritis Medications Production Mode & Process
9.2 Axial Spondyloarthritis Medications Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Axial Spondyloarthritis Medications Distributors
9.2.3 Axial Spondyloarthritis Medications Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.